PTC-AADC (formerly GT-AADC and AGIL-AADC) is an experimental treatment for aromatic L-amino acid decarboxylase (AADC) deficiency. Agilis Biotherapeutics originally developed the treatment, but the company was acquired by PTC Therapeutics, which is now developing the treatment. 

What is AADC deficiency?

AADC deficiency is a rare disease caused by mutations in a gene called DDC that provides the instructions necessary to make an enzyme called AADC. This enzyme is part of the biochemical pathway that produces neurotransmitters, or cell signaling molecules, such as dopamine and serotonin, which are vital to communication between nerve cells.

Without enough AADC enzyme, the brain cannot make enough serotonin and dopamine. This leads to physical and mental developmental delays from a young age; children with this disease have muscle weakness and muscle stiffness or spasms.

How does PTC-AADC work?

PTC-AADC is a gene therapy — it contains a virus (modified so it cannot cause disease) to transmit a healthy copy of the DDC gene to nerve cells. The cells use the gene to make functional AADC enzymes. The goal of the therapy is to increase the amount of AADC enzyme available. 

Doctors must administer the gene therapy via a surgical procedure that introduces the virus to an area of the brain called the putamen, which normally provides most of the dopamine that the brain requires.

Because this treatment is still experimental, there are questions that researchers must answer before it can move to the clinic. For example:

  • How old do patients need to be to receive the treatment successfully?
  • If patients receive the treatment at a young age, can it counter or prevent the symptoms of AADC deficiency?
  • Is a single administration of the virus sufficient to treat AADC deficiency, or will patients need multiple administrations over their lifetime?

PTC-AADC in clinical trials

A Phase 1/2 clinical trial (NCT01395641) tested the safety and efficacy of PTC-AADC in treating AADC deficiency. Ten patients older than 24 months took part. Researchers injected PTC-AADC into the brains of the patients, who were assessed at baseline (prior to surgery) and three, six, nine, and 12 months after surgery. 

The results of the trial appeared in The Lancet Child & Adolescent Health in December 2017. All patients tolerated the surgery and treatment well. The trial met its primary objectives with improvements seen in the peabody developmental motor scales (PDMS-2, a measure of motor development in children). Throughout the study, 31 treatment-related adverse events occurred, one of which was severe. No treatment-related adverse events led to hospital admission or death.

A Phase 2 clinical trial (NCT02926066) was built upon the previous trial and assessed the safety and efficacy of an increased dosage of the viral treatment in 10 patients. The primary outcome measure was motor developmental milestones as assessed by PDMS-2. The researchers also recorded adverse events and assessed patients for two years following treatment.

The researchers collated the results of the trial with five years’ worth of data from the Phase 1/2 trial. The findings were published in the journal Neurology in April 2019, and showed clinically meaningful improvements in the patients in the PDMS-2 total score and single-item motor developmental milestones versus natural history controls. All patients had sustained dopamine production. No new safety concerns were present five years post-treatment.

Researchers also presented preliminary results from three clinical trials at the 48th Annual Meeting of the Child Neurology Society in October 2019. All patients who received PTC-AADC showed decreased oculogyric crises (involuntary upward eye movement, which is a characteristic symptom of AADC deficiency). Treated patients also improved their ability to sit, walk, and talk. Benefits lasted for up to five years after treatment.

Based on these findings, PTC plans to seek approval for PTC-AADC in the U.S. and Europe.

 

Last updated: May 11, 2020

***

AADC News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare providers with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Emily holds a Ph.D. in Biochemistry from the University of Iowa and is currently a postdoctoral scholar at the University of Wisconsin-Madison. She graduated with a Masters in Chemistry from the Georgia Institute of Technology and holds a Bachelors in Biology and Chemistry from the University of Central Arkansas. Emily is passionate about science communication, and, in her free time, writes and illustrates children’s stories.
Total Posts: 0
Özge has a MSc. in Molecular Genetics from the University of Leicester and a PhD in Developmental Biology from Queen Mary University of London. She worked as a Post-doctoral Research Associate at the University of Leicester for six years in the field of Behavioural Neurology before moving into science communication. She worked as the Research Communication Officer at a London based charity for almost two years.
×
Emily holds a Ph.D. in Biochemistry from the University of Iowa and is currently a postdoctoral scholar at the University of Wisconsin-Madison. She graduated with a Masters in Chemistry from the Georgia Institute of Technology and holds a Bachelors in Biology and Chemistry from the University of Central Arkansas. Emily is passionate about science communication, and, in her free time, writes and illustrates children’s stories.
Latest Posts
  • dystonic crisis
  • medications and AADC deficiency
  • AADC support network
  • sleep issues, AADC